| Category | Details |
| Definition | Metabolic Syndrome (MetS) is a cluster of conditions—including obesity, hypertension, hyperglycemia, and dyslipidemia—that increase the risk of cardiovascular disease and diabetes. |
| Global Epidemiology | Affects an estimated 1 billion people worldwide, with increasing prevalence due to sedentary lifestyles and poor dietary habits. |
| Up to 25% of adults globally meet the diagnostic criteria for MetS. |
| Commonly associated with urbanization and lifestyle changes. |
| Prevalence in Key Regions | United States: Approximately 34.7% of adults affected (~88 million individuals). |
| European Union: ~23% prevalence, particularly in Mediterranean countries. |
| India: Estimated 420 million cases, with higher rates in urban areas. |
| China: ~343 million cases, driven by urbanization and dietary changes. |
| Caribbean: Prevalence estimated at 20–30% of adults, representing ~6–8 million people. |
| Medicinal Cannabis Approvals | United States (FDA): No specific approvals for MetS, but research ongoing for obesity, diabetes, and inflammation. |
| European Union (EMA): No direct approvals; cannabinoids studied for weight management and insulin sensitivity. |
| Canada: CBD products authorized for general wellness; no specific approvals for MetS. |
| Australia (TGA): Approved cannabinoids for managing chronic inflammation and pain associated with MetS. |
| Israel: Authorized for research and treatment of metabolic disorders since 2014. |
| South Africa: Approved CBD for inflammation management in 2019, potentially benefiting MetS. |
| Therapeutic Cannabinoids | CBD (Cannabidiol): Demonstrates anti-inflammatory and insulin-sensitizing effects; reduces oxidative stress. |
| THCV (Tetrahydrocannabivarin): Improves insulin sensitivity and glucose metabolism; potential appetite suppressant. |
| CBG (Cannabigerol): Exhibits anti-obesity and lipid-lowering properties in early studies. |
| THC (Tetrahydrocannabinol): Appetite modulation at low doses; psychoactive effects limit use in MetS. |
| Mechanism of Action | CBD: Activates CB2 receptors, reducing inflammation and oxidative stress; modulates lipid metabolism through PPARγ pathways. |
| THCV: Acts as a CB1 antagonist, reducing appetite and improving glucose regulation. |
| CBG: Inhibits fat cell accumulation and promotes lipid breakdown. |
| Key Clinical Studies | Jadoon et al., 2016: Demonstrated improved glycemic control and reduced fasting glucose. |
| Wargent et al., 2013: This study demonstrated that THCV improved insulin sensitivity and reduced glucose intolerance in diet-induced obese (DIO) mice and genetically obese (ob/ob) mice. The study found that THCV increased insulin sensitivity, indicating its potential as a therapeutic agent for managing obesity-related metabolic disorders |
| Hussain et al., 2020: Cannabinoids reduced systemic inflammation and improved lipid profiles. |
| Dosage Guidelines | CBD (Oral): Starting dose 5–10 mg/day; titrate to 20–50 mg/day based on response. |
| THCV (Experimental): Early trials suggest 10–20 mg/day for appetite and glucose control. |
| CBG (Experimental): Initial studies use 10–15 mg/day for lipid-lowering effects. |
| Administration Methods | Oral Capsules: Consistent dosing; preferred for MetS management. |
| Sublingual Oils: Rapid absorption; used for acute inflammation reduction. |
| Inhalation: Rarely used for MetS; dosing variability limits its application. |
| Adverse Effects | CBD: Mild side effects like fatigue, diarrhea, appetite changes; rare liver enzyme elevation. |
| THCV: Minimal psychoactive effects; early studies report mild gastrointestinal discomfort. |
| CBG: Limited evidence; potential fatigue and dry mouth reported in early trials. |
| Research Gaps | Long-term safety and efficacy of cannabinoids like THCV and CBG in MetS treatment remain under-researched. |
| Interaction studies with standard MetS medications needed for clinical integration. |
| Opportunities in the Caribbean | High Prevalence: ~6–8 million adults affected, with limited access to metabolic healthcare services. |
| Cannabis Clinics: Establishing cannabinoid-focused clinics could provide local solutions and attract international patients seeking metabolic treatments. |
| Research Hub: Leveraging regional expertise to develop cannabinoid-based therapies for MetS. |
